文献速递先天性心脏病外科瓣膜外科

20岁以下患者肺动脉位置同种移植物与牛颈静脉导管性能比较

Comparison of homografts and bovine jugular vein conduits in the pulmonary position in patients <20 years of age.
PubMed 文献 · J Thorac Cardiovasc Surg · 2021-12-15

在澳大利亚3个中心≤20岁先天性心脏病患者中比较674根导管(肺动脉同种移植物305根、牛颈静脉导管303根、主动脉同种移植物66根),中位随访6.4年;>15 mm时肺动脉同种移植物在再干预、结构性瓣膜退化和感染性心内膜炎方面优于牛颈静脉导管和主动脉同种移植物,≤15 mm时各类型性能相似。

要点

  • 5年和10年免于再干预率:肺动脉同种移植物92%和80%,牛颈静脉导管74%和37%,主动脉同种移植物75%和47%。
  • 牛颈静脉导管较肺动脉同种移植物再干预风险更高(P<.001)和结构性瓣膜退化风险更高(P<.001)。
  • 感染性心内膜炎发生率:肺动脉同种移植物1%,牛颈静脉导管10%,主动脉同种移植物1.5%。

核心结论

  • 在年龄<20岁、导管>15 mm的患者中,肺动脉同种移植物在肺动脉位置优于牛颈静脉导管和主动脉同种移植物。
  • 主动脉同种移植物与牛颈静脉导管的性能相当。
  • 小导管(≤15 mm)各类型性能相似。

研究设计与样本

  • 回顾性多中心研究,纳入澳大利亚3个中心≤20岁先天性心脏病患者,共674根导管:肺动脉同种移植物305根(45%)、牛颈静脉导管303根(45%)、主动脉同种移植物66根(10%)。
  • 采用倾向性评分匹配平衡肺动脉同种移植物与牛颈静脉导管的比较。

主要发现

  • 中位随访6.4年(四分位距3.1-10.7年)。
  • 5年和10年免于再干预率:肺动脉同种移植物92%和80%,牛颈静脉导管74%和37%,主动脉同种移植物75%和47%。
  • 牛颈静脉导管较肺动脉同种移植物再干预风险更高(P<.001)和结构性瓣膜退化风险更高(P<.001)。
  • 倾向性评分匹配(对导管>15 mm有效)证实上述发现;>15 mm的主动脉同种移植物较>15 mm的肺动脉同种移植物再干预风险更高(P<.001)和结构性瓣膜退化风险更高(P<.001)。
  • 主动脉同种移植物与牛颈静脉导管在所有尺寸上性能相似(再干预P=.94;结构性瓣膜退化P=.72)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the performance of homografts and bovine jugular vein (BJV) conduits in the pulmonary position. METHODS: All patients with congenital heart disease up to age 20 years who underwent pulmonary valve replacement with homografts or BJV at 3 centers in Australia were evaluated. There were 674 conduits, with 305 (45%) pulmonary homografts (PHs), 303 (45%) BJV conduits, and 66 (10%) aortic homografts (AHs). Endpoints were freedom from reintervention, structural valve degeneration (SVD), and infective endocarditis (IE). Propensity score matching was used to balance the comparison of PH and BJV conduits. RESULTS: The median follow-up was 6.4 years (interquartile range, IQR, 3.1-10.7 years). Freedom from reintervention at 5 and 10 years was 92% and 80%, respectively, for PH, 74% and 37% for BJV, and 75% and 47% for AH. BJV conduits had a higher risk of reintervention (P < .001) and SVD (P < .001) compared with PHs. These findings were confirmed with propensity score matching valid for conduit size >15 mm. AHs >15 mm had a higher risk of reintervention (P < .001) and SVD (P < .001) compared with PHs >15 mm. The performance of AHs and BJV conduits was similar across all sizes (reintervention, P = .94; SVD, P = .72). The incidence of IE was 1% for PH, 10% for BJV, and 1.5% for AH. CONCLUSIONS: In patients age <20 years with a conduit >15 mm, PHs outperformed BJV conduits and AHs in the pulmonary position. The performance of AH and BJV was comparable. Small conduits (≤15 mm) had similar performance across all conduit types.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Marathe SP, Hussein N, Wallace FRO, et al. Comparison of homografts and bovine jugular vein conduits in the pulmonary position in patients <20 years of age. J Thorac Cardiovasc Surg. 2021. PMID: 35058063. doi:10.1016/j.jtcvs.2021.11.087

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。